OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer – a ctDNA-guided phase II randomised approach. Study protocol

Figures & data

Figure 1. Study flow. ctDNA, circulating tumour deoxyribonucleic acid; R, randomisation.

Table 1. Overview of conclusion on circulating tumour-marker status based on molecular analysis.

Circulating tumour-marker status	Results of molecular analysis
Circulating tumour-marker positive	+ Detection of CRC mutation(s) by ddPCR + Detection of NPY methylated DNA
	+ Detection of CRC mutation(s) by ddPCR – Detection of NPY methylated DNA
	– Detection of CRC mutation(s) by ddPCR + Detection of NPY methylated DNA
Circulating tumour-marker negative	– Detection of CRC mutation(s) by ddPCR – Detection of NPY methylated DNA

Data availability statement

The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.